全球首款获批cAMP偏向型GLP-1：先为达携手辉瑞加速埃诺格鲁肽商业化进程

Core Insights - The strategic collaboration between Xianweida Biotech and Pfizer China focuses on the commercialization of Enoglutide injection, the first cAMP biased GLP-1 receptor agonist approved for adult type 2 diabetes treatment in China [1][2] - Pfizer will hold exclusive commercialization rights for Enoglutide in mainland China, while Xianweida will act as the marketing authorization holder (MAH) responsible for R&D, registration, production, and supply [1] - The agreement includes potential payments to Xianweida totaling up to $495 million, which encompasses upfront payments and milestone payments related to registration and sales [1] Clinical Efficacy - Enoglutide has demonstrated superior efficacy and safety in multiple clinical studies, with an average weight reduction of 15.1% in the Chinese population after adjusting for the placebo group [1] - 92.8% of patients achieved clinically significant weight loss, and over 80% of patients met blood sugar targets (HbA1c <7.0%) [1] Strategic Vision - The CEO of Xianweida, Dr. Pan Hai, expressed optimism about integrating Xianweida's innovative scientific achievements with Pfizer China's commercial capabilities to advance the commercialization of Enoglutide [2] - The collaboration aims to leverage the "Weight Management Year" as a significant opportunity to provide diverse and high-quality treatment options for patients with obesity and metabolic diseases in China [2]